Myo-Inositol Manufacturing, Supply & Shortage History: What Every Woman Taking It Should Know

What Myo-Inositol Actually Is and Why the Source Matters

Myo-inositol is a naturally occurring sugar alcohol, classified as a member of the vitamin B family, though the body can synthesize it from glucose. As a supplement, it is the most biologically active of the nine inositol stereoisomers and is the form most studied for women's health outcomes.

The specific form you take matters because different stereoisomers have different receptor affinities. Myo-inositol and D-chiro-inositol act through distinct but complementary insulin-signaling pathways, which is why most clinically studied formulations combine them at a 40:1 ratio, mirroring the approximate physiological ratio found in human plasma.

Why Women Are the Primary Consumers

The vast majority of inositol supplement sales in the US and Europe are driven by women. The primary indications studied in women include:

• Polycystic ovary syndrome (PCOS) and associated anovulation
• Insulin resistance and metabolic dysfunction in PCOS
• Gestational diabetes prevention
• Thyroid autoimmunity (particularly Hashimoto thyroiditis)
• Anxiety and mood symptoms tied to hormonal fluctuations in perimenopause

Because this is a supplement market dominated by female buyers with specific clinical needs, supply disruptions are not merely an inconvenience. For a woman trying to conceive with PCOS, running out of inositol mid-cycle can directly affect ovulation timing and fertility outcomes.

How Myo-Inositol Is Manufactured: From Grain to Capsule

The Raw Material: Phytic Acid Hydrolysis

Commercial myo-inositol production begins with phytic acid (inositol hexaphosphate, or IP6), which is found in high concentrations in the bran layers of cereal grains, particularly corn and rice. The two dominant feedstocks are:

1. Corn steep liquor, a byproduct of corn wet-milling that is abundant and relatively cheap in corn-growing regions
2. Rice bran, used more commonly in Japanese and some South Asian facilities

Phytic acid is extracted, then enzymatically or acid-hydrolyzed to remove the phosphate groups, yielding myo-inositol in its free form. Enzymatic hydrolysis using phytase enzymes produces higher purity with fewer acidic byproducts compared to older acid-hydrolysis methods, though the latter remains more common in lower-cost production runs.

Purification and Crystallization

After hydrolysis, the crude inositol mixture goes through a series of filtration, ion-exchange chromatography, and crystallization steps to reach pharmaceutical-grade purity (typically 98% or higher). This step is where production costs diverge significantly between manufacturers. Cutting corners on purification can leave residual phytate, heavy metals from the grain matrix, or other inositol isomers in the finished material.

Converting Myo-Inositol to D-Chiro-Inositol

D-chiro-inositol is not extracted directly from plant material in useful quantities. Instead, it is produced by epimerization of myo-inositol, an enzymatic conversion that flips a single hydroxyl group. This step requires additional enzymatic capacity and quality controls, making D-chiro-inositol more expensive per gram than myo-inositol and more sensitive to supply constraints.

Finished Product Manufacturing

Bulk active pharmaceutical ingredient (API) is then shipped to contract manufacturers, often in the US, Europe, or India, who encapsulate or blend it into powder sachets. The finished product is then sold under dozens of brand names, all drawing from the same narrow pool of upstream suppliers.

Where the World's Myo-Inositol Comes From

China's Dominance

China produces an estimated 70-80% of the world's commercial myo-inositol supply, primarily through facilities in Shandong, Jiangsu, and Hebei provinces, where corn processing infrastructure is dense. The main producers include large chemical and nutraceutical groups, but even within China the actual synthesis capacity is concentrated among roughly five to eight major facilities.

This concentration is economically logical, since corn wet-milling byproducts are most efficiently monetized at scale. The problem is that a quality enforcement action, a facility fire, a labor dispute, or an export restriction in a single Shandong plant can simultaneously affect dozens of supplement brands sold in US pharmacies and online retailers.

Japan's Role in Higher-Purity Grades

Japan has historically produced a smaller but higher-purity fraction of global inositol, with some manufacturers holding pharmaceutical-grade certifications suitable for European Pharmacopoeia standards. Japanese production is typically used for clinical-grade formulations and for European markets where regulatory standards for supplements are stricter than in the US.

European and US Domestic Capacity

Genuine domestic production in the US is minimal. A small number of European toll manufacturers can process inositol, but they rely on imported Chinese or Japanese bulk material. There is no large-scale North American phytic acid-to-inositol production pathway currently operating.

Shortage History: What Has Actually Happened

2018 to 2019: The First Documented Shortage Wave

The first widely reported disruption in the US consumer market occurred in late 2018 and extended through mid-2019. The proximate cause was a combination of factors: Chinese environmental enforcement actions that temporarily shuttered or reduced output from several Shandong chemical facilities, overlapping with a surge in demand driven by growing clinical awareness of inositol for PCOS.

During this period, multiple supplement brands went out of stock simultaneously on major retail platforms, and prices for the remaining inventory increased by an estimated 30-50% at the wholesale level. Women who relied on specific formulations, particularly the 40:1 myo-inositol/D-chiro-inositol ratio products that had been recommended by their reproductive endocrinologists, found those exact products unavailable for weeks to months.

2020 to 2021: COVID-19 Supply Chain Compression

The COVID-19 pandemic introduced a second, broader supply chain disruption that affected inositol alongside hundreds of other supplement ingredients. Factors included:

• Port congestion in Shanghai and Tianjin delaying bulk shipments by 6-12 weeks
• Increased global demand for supplements generally
• Reduced air freight capacity for smaller urgent orders
• Factory workforce reductions during Chinese lockdown periods in early 2020

US importers reported difficulty securing consistent supply of pharmaceutical-grade myo-inositol bulk material from their usual Chinese contract suppliers, with lead times extending from the standard 8-12 weeks to 20-28 weeks in some cases.

2022 to 2023: The 40:1 Ratio Formulation Crunch

A more specific shortage emerged in 2022 affecting the combined 40:1 myo-inositol/D-chiro-inositol products rather than plain myo-inositol powder. The bottleneck was D-chiro-inositol supply, since its production via enzymatic epimerization requires specialized capacity that had not scaled proportionally with the dramatic increase in demand for the combined formulation.

This is a clinically meaningful distinction for women. Plain myo-inositol remained relatively available, but the 40:1 combination products supported by the strongest clinical evidence for PCOS and ovulation became specifically hard to find. A woman whose reproductive endocrinologist had recommended the combination formulation based on the Unfer et al. 2017 meta-analysis showing superiority of combined inositol over myo-inositol alone for hormonal and metabolic outcomes in PCOS faced a real clinical decision: switch to a less-studied formulation, pay significantly higher prices from remaining inventory, or temporarily discontinue.

2024 to 2025: Current State

As of mid-2025, the acute shortage of 40:1 combination products has eased, but the underlying structural vulnerabilities remain. Prices for quality-tested products are 20-35% higher than pre-2020 baselines. Brand proliferation has increased, with hundreds of new inositol products entering the market, but third-party testing data suggest that purity and isomer accuracy vary considerably across brands. The FDA does not verify supplement label claims before sale.

What Shortages Mean for Women at Different Life Stages

Reproductive Years: PCOS and Ovulation

For women in their reproductive years using inositol to support ovulation and cycle regularity in PCOS, a sudden supply disruption can mean a return to anovulatory cycles within four to eight weeks of stopping. Myo-inositol at 4 g per day improved ovulation rates by approximately 62% versus 20% in controls in the meta-analysis by Unfer et al. That is a meaningful therapeutic effect that evaporates when supply runs out.

If you are trying to conceive and using inositol as part of your cycle management, maintaining a 60-90 day backup supply is a reasonable strategy. Discuss this with your reproductive endocrinologist, since storing powder products requires attention to humidity and temperature.

Trying to Conceive

Women actively trying to conceive who are using inositol as a first-line intervention for PCOS-related anovulation should have a clear fallback plan with their care team before a shortage forces an unplanned switch. Alternatives that have been studied for ovulation induction in PCOS include metformin, letrozole, and clomiphene, though each carries a different risk profile and requires a prescription.

Pregnancy

Myo-inositol has been studied specifically in pregnancy for gestational diabetes prevention in women at high risk, including those with prior PCOS. A shortage during pregnancy, when a woman may have been started on inositol as a non-pharmacological intervention for glucose regulation, can prompt an unnecessary switch to pharmacological management with more established but more complex risk profiles.

Perimenopause and Post-Menopause

Women in perimenopause sometimes use myo-inositol for mood stabilization, insulin sensitivity (metabolic syndrome risk rises substantially in the menopause transition), and thyroid autoimmunity management. Data in this age group are thinner than in reproductive-age PCOS, and the evidence gap is real. Most perimenopausal inositol data is extrapolated from younger PCOS cohorts. Shortages in this group, while not tied to fertility urgency, still represent a disruption to a multi-month supplementation protocol where consistency matters for observing metabolic effects.

Pregnancy and Lactation: Safety, Evidence, and What to Do During a Shortage

Myo-inositol does not have an FDA pregnancy category because it is sold as a supplement, not a drug. This means no formal Pregnancy Category A through X applies, and the FDA's newer labeling framework for prescriptions does not govern it either.

Human Data in Pregnancy

Several randomized controlled trials have specifically studied myo-inositol in pregnancy for gestational diabetes prevention in high-risk women. A 2015 trial by D'Anna et al. Found that 4 g myo-inositol daily from the first trimester through delivery reduced gestational diabetes incidence from 17.4% to 6.3% in women at risk. No increase in fetal anomalies, preterm birth, or neonatal adverse outcomes was reported in these trials.

The evidence is reassuring but not definitive. Trial sizes are relatively small by drug-approval standards, and long-term neonatal follow-up data beyond the newborn period are limited. Women should discuss risk-benefit with their OB-GYN or maternal-fetal medicine specialist rather than self-managing inositol through pregnancy without clinical oversight.

Lactation

Myo-inositol is present naturally in human breast milk, with concentrations ranging from approximately 50 to 200 mg per liter depending on lactation stage, which suggests the newborn is routinely exposed to physiological amounts. Supplemental maternal myo-inositol would be expected to increase milk concentrations modestly, but direct pharmacokinetic studies in lactating women are absent from the published literature. This is an evidence gap. The LactMed database at NIH does not list a specific contraindication, but the absence of data is not the same as documented safety.

Contraception Note

Myo-inositol is not teratogenic in available animal or human data, and it does not require contraception as a condition of use the way teratogenic medications do. For women with PCOS using inositol to improve ovulation, the restoration of ovulatory cycles is itself a reason to discuss contraception if pregnancy is not desired. Improved ovulation is a therapeutic success, not a safety concern, but it does mean conception becomes possible when it may not have been before.

How to Evaluate a Myo-Inositol Product When Supply Is Constrained

When your usual brand is unavailable, the following criteria can help you select an alternative without compromising clinical outcomes.

Third-Party Testing

Look for a certificate of analysis (COA) from an independent laboratory, ideally NSF International, USP, or Informed Sport. The COA should confirm:

• Myo-inositol content matches label claim within 10%
• D-chiro-inositol content matches label claim (for combination products)
• Absence of heavy metals (lead, arsenic, cadmium, mercury) at or below USP limits
• No detectable other inositol isomers substituted for the declared stereoisomers

The 40:1 Ratio Is Not Negotiable for PCOS

Products that deviate significantly from the 40:1 myo-inositol-to-D-chiro-inositol ratio are not equivalent to those studied in the PCOS trials. Some products offer a 5:1 ratio or pure D-chiro-inositol, which carry different physiological effects and lack the same evidence base. Do not substitute freely between ratios without guidance from your care provider.

Powder vs. Capsule Bioavailability

There is no high-quality human pharmacokinetic trial directly comparing powder sachets to capsules for myo-inositol in women. What is known is that dissolution speed differs, with powders dissolving faster in gastric fluid. For practical purposes, capsule and powder forms at equal doses are generally considered clinically interchangeable, though women with slower gastric motility (common in hypothyroidism, which frequently co-occurs with PCOS) might theoretically absorb powders more efficiently.

Who This Is Right For and Who Should Be Cautious

Women Most Likely to Benefit

• Women with PCOS and insulin resistance, particularly those not yet on or who prefer to avoid metformin
• Women with PCOS and anovulatory infertility as an adjunct to or alternative to ovulation-induction medications, under specialist guidance
• Women with high-risk pregnancy factors for gestational diabetes, under obstetric guidance
• Women with Hashimoto thyroiditis and elevated thyroid peroxidase antibodies (limited but emerging evidence)

Women Who Should Use Caution or Consult First

• Women on antipsychotics or lithium (inositol may theoretically interact with phosphoinositide signaling pathways affected by these medications)
• Women with bipolar disorder (myo-inositol has been studied as an adjunct in bipolar depression; use in this context should be coordinated with psychiatry)
• Women with renal impairment (inositol is renally cleared; accumulation data in CKD are absent)
• Women in perimenopause using inositol for metabolic reasons without a confirmed diagnosis of insulin resistance: the evidence base is thinner, and better-studied interventions may be more appropriate first

What a Shortage Means Practically: A Clinical Framework for Continuity

If your specific inositol formulation becomes unavailable, here is a structured approach:

1. Verify the shortage is real and not brand-specific. Check two or three other reputable brands with third-party COAs before assuming the ingredient itself is unavailable.
2. Contact your reproductive endocrinologist, OB-GYN, or women's-health NP before switching formulations. A ratio change or form change should be documented in your care plan.
3. Do not substitute pure D-chiro-inositol for the 40:1 combination. High doses of D-chiro-inositol alone have been associated with reduced oocyte quality in some data; the balance of the 40:1 ratio is physiologically intentional.
4. If inositol is temporarily unavailable and you are trying to conceive with PCOS, discuss bridging with your clinician. Metformin 500 mg twice daily is the most studied alternative for insulin sensitization in PCOS and has a more established evidence base in pregnancy if needed.
5. Maintain a 60-to-90-day supply when you find a quality product. Given the structural concentration of manufacturing, periodic shortages are not a historical anomaly. They are a foreseeable recurrence.

The Evidence Gap Specific to Women

Women have been underrepresented in pharmaceutical trials for decades, but inositol is a partial exception. The PCOS literature is almost entirely conducted in women, which means the mechanistic evidence and dosing data are more directly applicable than for many drugs. This is a genuine strength of the inositol evidence base for female readers.

Where the gap exists is in older women. The majority of randomized controlled trials in inositol enrolled women under 40 with PCOS, and data on perimenopausal or post-menopausal women using inositol for metabolic or thyroid indications remain largely observational or extrapolated. Long-term safety data beyond 12 months of continuous use are also sparse across all age groups.

The honest clinical summary: for reproductive-age women with PCOS, inositol has some of the strongest supplement evidence available. For women outside that profile, the evidence is promising but insufficient to make strong clinical recommendations without acknowledging that extrapolation is occurring.